Compositions and methods of treating a t cell mediated disorder

Abstract

A method of generating a CD4 + FoxP3 + Treg cell, the method includes administering at least one complement antagonist to a naive CD4 + T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4 + T cell, induce TGF-β1 expression of the CD4 + T cell, and induce differentiation of the of the naive CD4 + T cell into a CD4 + FoxP3 + Treg cell.

Having described the invention, the following is claimed: 
     
         1 . A method of treating inflammation in a subject, the method comprising:
 administering at least one complement antagonist to a naive CD4 +  T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4 +  T cell, induce TGF-β1 expression of the CD4 +  T cell, and induce differentiation of the of the naive CD4 +  T cell into a CD4 + FoxP3 +  Treg cell; and   administering a therapeutically effective amount of the CD4 + FoxP3 +  Treg cells to the subject.   
     
     
         2 . The method of  claim 1 , wherein the at least one complement antagonist substantially inhibits interaction of at least one of C3a or C5a with the C3aR or C5aR of the CD4 +  T cell. 
     
     
         3 . The method of  claim 2 , the at least one complement antagonist being selected from the group consisting of a small molecule, a polypeptide, and a polynucleotide. 
     
     
         4 . The method of  claim 3 , the polypeptide comprising an antibody directed against at least one of C3, C5, C3 convertase, C5 convertase, C3a, C5a, C3aR, or C5aR. 
     
     
         5 . The method of  claim 2 , the step of administering the at least one complement antagonist further including administering to the naive CD4 +  T cell a C3aR antagonist and an a C5aR antagonist. 
     
     
         6 . The method of  claim 2 , the step of administering the at least one complement antagonist further including administering to the cell a C3a antagonist and a C5a antagonist. 
     
     
         7 . The method of  claim 1 , the CD4 + FoxP3 +  Treg cells being administered systemically to the subject being treated. 
     
     
         8 . The method of  claim 1 , wherein the complement antagonist substantially induces naive CD4 + cell expression of CD25, CTLA-4, FoxP3, DAF and C5L2, downregulates dendritic cell B7/CD40 and CD4 +  effector cell CD28/CD40 ligand costimulatory molecule expression, and inhibits dendritic cell C5a/C3a production and CD4 +  cell C5aR/C3aR signal transduction in the subject. 
     
     
         9 . The method of  claim 1 , further comprising the step of isolating the naive CD4 +  Tcells from a mammalian subject. 
     
     
         10 . The method of  claim 1 , further comprising the step of culturing the naive CD4 +  T cells in the presence of dendritic cells. 
     
     
         11 . The method of  claim 1 , further comprising the step of culturing the naive CD4 +  T cells with agents which promote the expansion and survival of CD4 + FoxP3 +  Treg cells. 
     
     
         12 . The method of  claim 11 , the one or more agents being selected from the group consisting of an anti-CD3/28, IL-2, TGF-β and combinations thereof. 
     
     
         13 . A method of treating a T cell mediated disease in a subject, the method comprising:
 administering to the subject a therapeutically effective amount of at least one complement antagonist and a pharmaceutically acceptable carrier, wherein the at least one complement antagonist substantially inhibits interaction of at least one of C3a or C5a with the C3a receptors (C3aR) and C5a receptors (C5aR) on interacting dendritic cells and CD4 + T cells in the subject.   
     
     
         14 . The method of  claim 13 , wherein the complement antagonist does not substantially systemic complement activation. 
     
     
         15 . The method of  claim 13 , wherein the T cell mediated disease is selected from the group consisting of achlorhydra autoimmune active chronic hepatitis, acute disseminated encephalomyelitis, acute hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, Alzheimer's disease, amyotrophic lateral sclerosis, ankylosing spondylitis, anti-gbm/tbm nephritis, antiphospholipid syndrome, antisynthetase syndrome, aplastic anemia, arthritis, atopic allergy, atopic dermatitis, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenia purpura, autoimmune uveitis, balo disease/balo concentric sclerosis, bechets syndrome, Berger's disease, Bickerstaff's encephalitis, blau syndrome, bullous pemphigoid, castleman's disease, chagas disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, chronic lyme disease, chronic obstructive pulmonary disease, churg-strauss syndrome, cicatricial pemphigoid, coeliac disease, cogan syndrome, cold agglutinin disease, cranial arteritis, crest syndrome, Crohns disease, Cushing's syndrome, Dego's disease, Dercum's disease, dermatitis herpetiformis, dermatomyositis, diabetes mellitus type 1, Dressler's syndrome, discoid lupus erythematosus, eczema, endometriosis, enthesitis-related arthritis, eosinophilic fasciitis, epidermolysis bullosa acquisita, essential mixed cryoglobulinemia, evan's syndrome, fibrodysplasia ossificans progressive, fibromyalgia, fibromyositis, fibrosing aveolitis, gastritis, gastrointestinal pemphigoid, giant cell arteritis, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-barre syndrome (gbs), Hashimoto's encephalitis, Hashimoto's thyroiditis, henoch-schonlein purpura, hidradenitis suppurativa, Hughes syndrome, inflammatory bowel disease (IBD), idiopathic inflammatory demyelinating diseases, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, iga nephropathy, inflammatory demyelinating polyneuopathy, interstitial cystitis, irritable bowel syndrome (ibs), Kawasaki's disease, lichen planus, Lou Gehrig's disease, lupoid hepatitis, lupus erythematosus, meniere's disease, microscopic polyangiitis, mixed connective tissue disease, morphea, multiple myeloma, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica, neuromyotonia, occular cicatricial pemphigoid, opsoclonus myoclonus syndrome, ord thyroiditis, Parkinson's disease, pars planitis, pemphigus, pemphigus vulgaris, pernicious anaemia, polymyalgia rheumatic, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive inflammatory neuropathy, psoriasis, psoriatic arthritis, raynaud phenomenon, relapsing polychondritis, Reiter's syndrome, rheumatoid arthritis, rheumatoid fever, sarcoidosis, schizophrenia, Schmidt syndrome, Schnitzler syndrome, scleritis, scleroderma, Sjögren's syndrome, spondyloarthropathy, sticky blood syndrome, still's disease, stiff person syndrome, sydenham chorea, sweet syndrome, takayasu's arteritis, temporal arteritis, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, undifferentiated spondyloarthropathy, vasculitis, vitiligo, Wegener's granulomatosis, Wilson's syndrome, Wiskott-Aldrich syndrome, hypersensitivity reactions of the skin, atherosclerosis, ischemia-reperfusion injury, myocardial infarction, and restenosis. 
     
     
         16 . The method of  claim 13 , the at least one complement antagonist being selected from the group consisting of a small molecule, a polypeptide, and a polynucleotide. 
     
     
         17 . The method of  claim 16 , the polypeptide comprising an antibody directed against at least one of C3, C5, C3 convertase, C5 convertase, C3a, C5a, C3aR, or C5aR. 
     
     
         18 . The method of  claim 13 , the step of administering the at least one complement antagonist further including administering to the subject an antibody directed against C5aR and an antibody directed against C3aR. 
     
     
         19 . The method of  claim 13 , the step of administering the at least one complement antagonist further including administering to the subject an antibody directed against C5a and an antibody directed against C3a. 
     
     
         20 . The method of  claim 13 , the complement antagonist and a pharmaceutically acceptable carrier being administered locally to a site of T cell mediated disease in the subject.